VIVS
VivoSim Labs
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About VIVS
Vivosim Labs, Inc.
A clinical stage biotechnology company dedicated to developing drug discovery and treatment methods using human tissue technology platforms
Biological Technology
Invalid Date
08/08/2016
NASDAQ Stock Exchange
12
03-31
Common stock
11555 Sorrento Valley Rd, Suite 100, San Diego, CA 92121
--
Founded in 2007, VivoSim Labs, Inc., is engaged in the development and commercialization of human tissue technology platforms that can be applied in drug discovery and development, biological research, and treatment of implanted damaged or degenerated tissues and organs. VivoSim plans to introduce three-dimensional human tissue to replicate the potential of natural human biology by constructing three-dimensional creations.
Company Financials
EPS
VIVS has released its 2024 Q3 earnings. EPS was reported at -0.40, versus the expected -0.50, beating expectations. The chart below visualizes how VIVS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
VIVS has released its 2025 Q3 earnings report, with revenue of 24.00K, reflecting a YoY change of 380.00%, and net profit of -3.45M, showing a YoY change of 4.36%. The Sankey diagram below clearly presents VIVS’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
